CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer Aug 12, 2024 8:30am EDT
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 Jun 27, 2024 8:30am EDT
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma Feb 01, 2024 8:30am EST
